Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Professor Juha Hartikainen

Kuopio University Hospital, Kuopio (Finland)

8 More presentations in this session

Presentation thumbnail

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Doctor T. Chao (Taipei, TW)

Presentation thumbnail

Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Doctor P. Rasmussen (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Associate Professor S. Choi (Daegu, KR)

Abstract Slides

Presentation thumbnail

Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Doctor G. Vanerio (Montevideo, UY)

Presentation thumbnail

Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease

Professor C. Coleman (Storrs, US)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

AF-CARE: “R” Rate and rhythm control

Congress Presentation

Interactive discussion and Q&A

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources